carfilzomib / Generic mfg. - LARVOL DELTA

First-Year Results of Isatuximab-Iberdomide Maintenance in MRD-Positive Newly Diagnosed Multiple Myeloma Patients Included in the Phase 3 MIDAS Trial (IMS 2026) - P3 | "While daratumumab plus lenalidomide maintenance has shown efficacy in recent studies (PERSEUS, AURIGA), no data are available regarding anti-CD38 combined with a CELMoD in maintenance... MIDAS (NCT04934475) is an ongoing phase 3 trial evaluating an MRD-adapted consolidation and maintenance strategy in TE-NDMM patients treated with six cycles of isatuximab, carfilzomib, lenalidomide, and dexamethasone (Isa-KRd)... Maintenance with isatuximab plus iberdomide after Isa-KRd induction and single or tandem ASCT is feasible with a manageable safety profile. This combination induced substantial MRD conversion during the first year of maintenance in patients remaining MRD-positive after consolidation. These findings support further evaluation of anti-CD38 plus CELMoD-based maintenance strategies in high-risk NDMM patients."

Clinical • IO biomarker • Minimal residual disease • P3 data • Hematological Disorders • Hematological Malignancies • Infectious Disease • Multiple Myeloma • Neutropenia

CERVINO: A Randomized Phase 3 Study of Etentamig vs Investigator's Choice of Standard Available Therapies in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) and Triple-Class Exposure (IMS 2026) - P3 | "Pts were randomized 1:1 to Etenta Q4W or SAT (carfilzomib + dexamethasone [Kd], elotuzumab + pomalidomide + d [EloPd], or selinexor + bortezomib + d [SVd]). In heavily pretreated pts with triple-class exposed RRMM, Etenta significantly improved ORR and PFS vs SAT, with an early positive OS signal. A single SUD andQ4Wdosing from initiation were associated with very low rates of CRS, ICANS, and ≥ G3 infections, reinforcing Etenta’s best-in-class safety potential. Data support Etenta monotherapy as a new standard of care with convenient dosing suitable for global outpatient and community use."

Clinical • Late-breaking abstract • P3 data • Hematological Malignancies • Infectious Disease • Inflammation • Multiple Myeloma

Effectiveness of anti-B-cell maturation antigen (BCMA)-targeting therapy after selinexor treatment. (ASCO 2023) - P1b/2, P2b, P3 | " We analyzed the effectiveness of non-cellular αBCMA (NCA) therapies in pts with MM treated in 4 clinical studies (STORM [NCT02336815]; STOMP [NCT02343042]; BOSTON [NCT03110562], XPORT-MM-028 [NCT04414475]) with selinexor + dexamethasone (Xd), with or without PIs, IMiDs, or αCD38 mAbs, followed by therapy with NCA...Thirty-seven pts (median age: 68, range: 40-87) received NCA therapy at any time following a selinexor regimen (Xd, n = 12; Xd + bortezomib, n = 9; Xd + pomalidomide, n = 6; Xd + daratumumab, n = 3; Xd + carfilzomib, n = 5; Xd + ixazomib, n = 2). NCAs included the ADC belantamab mafodotin (n = 28), the BiS teclistamab (n = 2), SEA-BCMA (n = 2), AMG 701 (n = 1), elranatamab (n = 1), MEDI2228 (n = 1), and investigational (n = 3; 2 had αBCMA bispecific antibodies and 1 had αBCMA BITE) (1 pt received 2 NCAs, belantamab and teclistamab)... In this cohort of heavily-pretreated pts with MM who received a selinexor regimen prior to NCA, overall..."

Hematological Malignancies • Immune Modulation • Multiple Myeloma • Oncology

Patient-reported Outcomes and Healthcare Provider Perspectives on Subcutaneous Isatuximab Delivery via On-body Injector Versus Manual Injection: Results From the Phase 2 IZALCO Study in Relapsed/Refractory Multiple Myeloma. (PubMed, Clin Lymphoma Myeloma Leuk) - P2 | "These findings support Isa SC OBI as the preferred administration method for patients and HCPs."

Journal • P2 data • Hematological Malignancies • Multiple Myeloma • Oncology • Pain

Safety of Concurrent Systemic Therapy and Palliative Radiation in Multiple Myeloma (ASTRO 2026) - "For neutropenia, 11/12 had RT to active marrow (10 axial); agents included targeted [daratumumab (8% of drug exposures), lenalidomide (8%), bortezomib (9%), pomalidomide (10%), carfilzomib (7%)], cytotoxic chemotherapy (68%) and teclistimab (33%). Among this cohort, CCRT toxicities caused no unintended treatment breaks. Grade 3 SAEs were mainly hematologic. Given frequent need for palliative RT in MM, these data suggest it is reasonable to consider CCRT with close hematologic monitoring."

Clinical • Hematological Malignancies • Multiple Myeloma • Oncology

Sequential Autologous Stem Cell Transplantation and Ciltacabtagene Autoleucel for Concurrent Multiple Myeloma and Presumptive Immunoglobulin Heavy- and Light-Chain Amyloidosis in a Patient With Systemic Lupus Erythematosus. (PubMed, Cureus) - "The patient was treated with induction chemotherapy (carfilzomib, daratumumab, lenalidomide), followed by an autologous stem cell transplant (ASCT) in month eight. Persistent, mild cytopenias and an elevated B-type natriuretic peptide (BNP) prompted ongoing post-CAR-T supportive care and evaluation for cardiac amyloidosis. This case highlights the feasibility of combining ASCT with BCMA-directed CAR T-cell therapy and its association with continued hematologic and renal improvement in highly complex patients with overlapping plasma cell dyscrasias, amyloid deposition, and autoimmune disease."

Journal • Amyloidosis • Cardiac Amyloidosis • Cardiovascular • Chronic Kidney Disease • Glomerulonephritis • Hematological Disorders • Hematological Malignancies • Immunology • Inflammatory Arthritis • Lupus • Multiple Myeloma • Nephrology • Oncology • Renal Disease • Systemic Lupus Erythematosus • Transplantation • IGH

Relapsed/refractory multiple myeloma with extramedullary plasmacytomas successfully rechallenged with humanized B-cell maturation antigen-directed chimeric antigen receptor T-cell immunotherapy in an advanced disease stage: A case report. (PubMed, Exp Ther Med) - "The present study describes the case of a 38-year-old man with RRMM and extensive cranial EMP who progressed after multiple prior therapies, including proteasome inhibitor- and immunomodulatory drug-based regimens, anti-CD38 therapy, carfilzomib-based therapy and a previous non-humanized BCMA CAR-T product. Due to rapidly progressive disease, the patient received bridging cytoreduction followed by fully humanized BCMA CAR-T therapy (equecabtagene autoleucel)...The present case suggests that fully humanized BCMA CAR-T therapy may remain effective in selected patients with RRMM and EMP, even after prior non-humanized BCMA CAR-T failure. These findings support further investigation into retreatment strategies and post-CAR-T maintenance approaches."

Journal • Hematological Malignancies • Multiple Myeloma • Oncology • Plasmacytoma

RETRACTION: Implications and Hidden Toxicity of Cardiometabolic Syndrome and Early-Stage Heart Failure in Carfilzomib-Induced Cardiotoxicity. (PubMed, Br J Pharmacol) - No abstract available

Journal • Cardiovascular • Congestive Heart Failure • Heart Failure • Metabolic Disorders

Carfilzomib, Iberdomide, and Dexamethasone (KID) in Patients with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): Updated Results from a Phase 1/2 Study (IMS 2026) - P1/2 | "Introduction: Standard upfront regimens demonstrate stringent complete response (sCR) rates of 10-15% following induction, and 40% following consolidation in patients (pts) with newly diagnosed multiple myeloma (NDMM). Induction tx with KID achieved 31% sCR/CR rates post ASCT overall and 31% in the high-risk NDMM pts at interim analysis, despite short tx duration. All pts were successfully mobilized. Further studies will evaluate KID with post-ASCT iber + elranatamab consolidation followed by iber maintenance."

Clinical • P1/2 data • Atrial Fibrillation • Cardiovascular • Hematological Disorders • Hematological Malignancies • Infectious Disease • Multiple Myeloma • Neutropenia • Targeted Protein Degradation • Thrombocytopenia • Transplantation • CRBN

Patient-Reported Outcomes (PROs) of Teclistamab-Based Treatment (Tx) in Relapsed/Refractory Multiple Myeloma (RRMM) After 1-3 Lines of Therapy (LOT) (IMS 2026) - P3 | "Introduction: Significant PFS and OS benefits were seen with teclistamab + daratumumab (Tec-Dara) in MajesTEC-3 (NCT05083169) and Tec monotherapy in MajesTEC-9 (NCT05572515) vs controls ( Dara + dexamethasone [dex] + pomalidomide/bortezomib [DPd/DVd] in MajesTEC-3; pomalidomide + bortezomib + dex or carfilzomib + dex [PVd/Kd] in MajesTEC-9) in patients (pts) with RRMM and 1-3 prior LOT. Tec-Dara and Tec improved HRQoL and significantly prolonged time to symptom worsening vs controls. Building on transformative PFS, OS, and safety data, PROs support pt-relevant benefits, complementing improved pt experience with monthly dosing and steroid-sparing regimens. Findings reinforce Tec-based tx as SoC in 2L+ RRMM across practice settings."

Clinical • Patient reported outcomes • Hematological Malignancies • Infectious Disease • Multiple Myeloma

Second Primary Malignancies After Autologous Transplantation for Multiple Myeloma in the Modern Treatment Era: Incidence, Risk Factors, and Prognostic Impact Using a Competing-Risk Approach (IMS 2026) - " We conducted a retrospective single-center study of 2,420 patients with MM who underwent upfront auto-HSCT following induction therapy that included at least one modern agent (bortezomib, lenalidomide, thalidomide, or carfilzomib). SPMs represent a relatively common late complication after auto-HSCT and independently confer a substantial adverse impact on long-term survival. Although competing mortality from MM remains higher, these findings highlight the importance of long-term surveillance and survivorship-focused risk assessment in MM patients undergoing auto-HSCT."

Clinical • Acute Myelogenous Leukemia • Basal Cell Carcinoma • Bladder Cancer • Bone Marrow Transplantation • Breast Cancer • Genetic Disorders • Genito-urinary Cancer • Hematological Malignancies • Kidney Cancer • Leukemia • Lung Cancer • Multiple Myeloma • Myelodysplastic Syndrome • Non-melanoma Skin Cancer • Oncology • Prostate Cancer • Renal Cell Carcinoma • Skin Cancer • Solid Tumor • Squamous Cell Carcinoma • Thoracic Cancer • Transplantation

Targeting of BIRC3 Sensitises Multiple Myeloma Cells to Proteasome Inhibitors (IMS 2026) - "Subsequent analysis using BV-6 in combination with PIs (carfilzomib/bortezomib) across five cell lines revealed at least an additive relationship between these drugs (Bliss Synergy score ≥ 5.08)...Importantly, similar synergistic effects were observed using a clinically relevant SM, tolinapant (Bliss Synergy score ≥ 12.44), further confirming BIRC3 as a PI-sensitiser gene... The results of this study reveal that BIRC3 is a PI-sensitiser gene which, when targeted therapeutically, increases PI sensitivity even in PI-resistant cells. Future work will aim to further delineate the role of TNFα signalling in SM/PI-induced cell death. Ultimately, the discovery of this synergistic drug combination could have important implications in developing new strategies to overcome treatment resistance in MM."

Hematological Malignancies • Multiple Myeloma • BIRC3 • CASP8 • CASP9 • TNFA

Single-Cell Transcriptomic Subtyping of Multiple Myeloma Identifies a Proliferative Tumor Subtype Associated with Treatment Resistance and Correlated with Aberrant Immune Patterns (IMS 2026) - " We used ~20K CD138+ scRNA-seq data collected from 41 relapsed MM patients, treated with daratumumab, carfilzomib, lenalidomide, and dexamethasone, at baseline, cycle 4, and cycle 10. We performed machine learning analysis of single-cell profiles from relapsed MM patients to discover robust subtypes, identifying 8 distinct disease subtypes including a Pr subtype, marked by elevated differentiation potential and proliferative gene signatures, and enrichment among non-responders across all treatment timepoints. These findings were validated in an independent MM patient cohort, where a gene signature of the Pr subtype was associated with an immunologically distinct tumor immune microenvironment. These findings support single-cell subtyping as a strategy for risk stratification in MM and nominate the Pr subtype as a putative resistance-associated biomarker for treatment with daratumumab-based therapy."

Hematological Malignancies • Multiple Myeloma • Oncology • CD4 • CD8 • SDC1

Shifting Landscapes in Triple-Class Exposed Multiple Myeloma in Latin America (LATAM): Real-World Outcomes with Bispecific Antibodies Versus Standard of Care (IMS 2026) - "Pts receiving BsAbs (teclistamab, talquetamab, or elranatamab) were compared with those treated with standard-of-care (SoC)-based salvage regimens. Belantamab mafodotin-treated pts were excluded from the primary comparative analysis due to limited sample size and retained for descriptive purposes only. SoC regimens were grouped as carfilzomib-based, pomalidomide-based, carfilzomib plus pomalidomide-based, chemotherapy-based, and other regimens... In this large real-world LATAM cohort of TCE-RRMM pts, BsAbs were associated with significantly improved response rates and survival outcomes compared with SoC, despite a population enriched with higher refractory burden and EMD prevalence. These findings support the effectiveness of BsAbs in routine clinical practice across LATAM and reinforce the importance of expanding access to novel immunotherapeutic strategies in the region."

Bispecific • Clinical • Real-world • Real-world evidence • Hematological Malignancies • Multiple Myeloma

Safety and Reliability of Isatuximab Subcutaneous On-Body Injector: Results Across the Phase 3 IRAKLIA, Phase 2 IZALCO, and Phase 1B TCD15484 Trials (IMS 2026) - " Pts with RRMM in IRAKLIA (N=263) and the Phase 1b expansion cohort (N=22) received 1400 mg Isa SC OBI plus pomalidomide and dexamethasone (d). In IZALCO, RRMM pts (N=64) received 1400 mg Isa SC OBI + carfilzomib (K)-d...Preinfusion medications included montelukast (C1), steroids, acetaminophen, and H1 antihistamines... These findings support overall low rates of IRRs and ISRs across trials, with >6000 (99.9%) Isa SC OBI injections successfully delivered. Isa SC OBI shows reproducible safety and reliability in IRAKLIA, IZALCO and Phase 1b trials, supporting it as a novel administration option for pts with MM and its potential for future exploration in at-home administration."

Clinical • P1 data • P2 data • P3 data • Hematological Malignancies • Multiple Myeloma

Repurposing Polyether Ionophores to Target Stem-Like Compartments and Microenvironmental Resistance in Multiple Myeloma (IMS 2026) - "We hypothesized that the polyether ionophores salinomycin (SAL) and monensin (MON), known to kill cancer stem-like cells in solid tumors, would target the Hoechst-low side-population (SP) compartment of MM...Both compounds synergized (Chou-Talalay CI< 0.9) with bortezomib, carfilzomib, lenalidomide, pomalidomide, doxorubicin, dexamethasone and melphalan, and significantly reduced subcutaneous RPMI-S xenograft growth in NSG mice without overt toxicity. SAL and MON are mechanistically convergent, stroma-resistant and cancer stem-like cell-directed agents that dismantle the bioenergetic, translational and survival machinery of the MM SP compartment, synergize with standard MM therapies and show in vivo efficacy without overt toxicity, supporting their further development for MM combination strategies. This study was supported by the NextGenerationEU project No.09I03-03-V04-00451 (JJ)."

Hematological Malignancies • Multiple Myeloma • Solid Tumor • ANXA5 • BBC3 • CCNB1 • CDKN1A • CHAC1 • CHEK1 • DDIT3 • EIF4EBP1 • GDF15 • IRF4 • MAP1LC3B • MYC • PMAIP1 • SDC1 • SIRT1 • SQSTM1

Real-World Teclistamab in Heavily Pretreated Relapsed/Refractory Myeloma: Deep Responses, Infections, and Extramedullary Escape (IMS 2026) - "Median prior therapy lines were 6; all patients were exposed to daratumumab, bortezomib, and lenalidomide. Prior carfilzomib and pomalidomide exposure were present in 10 (66.7%) and 11 (73.3%) patients...Grade 3 ICANS occurred in 1 patient and resolved with dexamethasone and anakinra... Teclistamab produced deep responses in heavily pretreated RRMM despite universal prior anti-CD38, proteasome inhibitor, and immunomodulatory drug exposure. However, early progression, EMD escape, and infections remained key outcome determinants despite proactive IVIG and tocilizumab-based supportive care. These findings support structured infection-prevention pathways and close monitoring for aggressive/EMD relapse during BCMA bispecific therapy."

Clinical • Real-world • Real-world evidence • Hematological Malignancies • Infectious Disease • Multiple Myeloma • Nephrology • Septic Shock

Real-World Outcomes of Daratumumab-Based Quadruplet Versus Triplet Regimens in Relapsed/Refractory Multiple Myeloma: A Multicenter Cohort (IMS 2026) - " We retrospectively analyzed 105 RRMM patients treated with DKd (daratumumab, carfilzomib, dexamethasone; n=27), DKPd (DKd plus pomalidomide; n=32), or DPd (daratumumab, pomalidomide, dexamethasone; n=46) between March 2020 and April 2026. In this real-world cohort, DKPd was associated with deeper responses and a favorable PFS trend compared with triplet regimens. These findings suggest that quadruplet therapy may be a reasonable option for selected patients with RRMM. However, these findings should be interpreted with caution given the retrospective, non-randomized design, limited sample size, and potential baseline imbalances, and are best considered hypothesis-generating."

Clinical • Real-world • Real-world evidence • Hematological Malignancies • Infectious Disease • Leukopenia • Multiple Myeloma • Neutropenia • Orthopedics • Pneumonia • Respiratory Diseases • Thrombocytopenia • B2M

Real-World Outcomes Following Second Line Treatment for Multiple Myeloma in Wales (IMS 2026) - "We categorised patients into six groups according to the second line regimen received: Daratumumab, Bortezomib and Dexamethasone (DVd), Carfilzomib, Lenalidomide and Dexamethasone (KRd), Ixazomib, Lenalidomide and Dexamethasone (IRd), Autologous stem cell transplant (Auto), Lenalidomide and Dexamethasone (Rd) and other Proteasome Inhibitor (PI)-based therapies (Other)...In 2025, the UK approved the anti-BCMA, antibody drug conjugate Belantamab Mafodotin, in combination with both Bortezomib and Dexamethasone (BVd) and Pomalidomide and Dexamethasone (BPd) for use at second line. In this real-world analysis of prescribing practice in Wales, our data shows that patients treated with DVd at second line achieved a superior 12mPFS, when compared to other triplet therapies. It also demonstrated an excellent 12mPFS for patients receiving an autologous stem cell transplant at second line. The data confirms the superior outcomes seen in patients with ISS I+II disease at diagnosis;..."

Clinical • Real-world • Real-world evidence • Hematological Malignancies • Multiple Myeloma

Real-World (RW) Characteristics, Treatment Patterns, and Outcomes in Triple-Class Exposed (TCE) Relapsed/Refractory Multiple Myeloma (RRMM) in Europe: Results from the HARMONY Big Data Platform (IMS 2026) - "Overall, 92% (n=458) were exposed to daratumumab, with 87% first receiving it in 2L and 5% in 1L...In the 3L cohort (n=152), >40 unique regimens were used; top regimens were carfilzomib-dexamethasone (dex) (16%), pomalidomide-dex (14%), and bortezomib-pomalidomide-dex (11%). Across the 2020+ subgroup (N=415), utilization of BsAbs in index LoT was low: teclistamab (18 [4%]), talquetamab (8 [2%]), elranatamab (2 [ < 1%])... European RW data, primarily from the Czech Republic, show fragmented treatment patterns for 3L+ TCE RRMM. Pts relapse quickly and survival worsens with later LoT. Despite the approval of novel immunotherapies, RW uptake remains limited and outcomes continue to be poor, highlighting the need for more effective and broadly accessible therapies."

Clinical • Real-world • Real-world evidence • Hematological Malignancies • Multiple Myeloma

Real Life Data of Belantamab Mafodotin for Patients with Early Relapsed Multiple Myeloma (IMS 2026) - "Introduction: Belantamab mafodotin (BELA) was recently approved for patients with relapsed/refractory multiple myeloma (RRMM) who received at least one prior line, in combination with bortezomib (BOR) or pomalidomide (POM)...Sixteen (28%) pts received BELA+proteosome inhibitor (PI) (14 BOR, 2 carfilzomib); 30 (52.6%) pts received BELA+immunomodulatory drug (IMiD) (26 POM, 4 lenalidomide (LEN))... Belantamab mafodotin shows significant anti-myeloma activity in early RRMM pts with high rate of daratumumab exposure in a real-world setting with a manageable safety profile."

Clinical • Cardiovascular • Congestive Heart Failure • Febrile Neutropenia • Gastrointestinal Disorder • Heart Failure • Hematological Malignancies • Infectious Disease • Multiple Myeloma • Myocardial Infarction • Neutropenia • Ophthalmology • Thrombocytopenia

Propensity Score Weighting Analysis of the KPD Regimen as Salvage Therapy in Newly Diagnosed Multiple Myeloma Patients with Suboptimal Response or Intolerance to V-Based Regimens (IMS 2026) - "Introduction: The aim of this study is to investigate the clinical efficacy and safet y of the combination therapy of Carfilzomib , Pomalidomide, and dexamethasone (KPd) as a salvage treatment in newly diagnosed multiple myeloma (NDMM) patients with poor efficacy o r intolerance to first-line bortezomib (V-base) regimen, and to compare it with continuing the original regimen or replacement chemotherapy drugs, providing real-world evidence for optimi zing clinical treatment strategies. For NDMM patients with p oor efficacy or intolerance to first-line V-base regimen, early upgrading to KPd regimen can significantly improve the depth of remissio n and overcome refractory status. Although it is accompanied by high hematological toxicity and infection risk, it has significant clinical benefits u nder close monitoring. This strategy is particularl y suitable for salvage treatment scenarios with severe baseline conditions and high-risk stages."

Clinical • Cardiovascular • Congestive Heart Failure • Heart Failure • Hematological Disorders • Hematological Malignancies • Infectious Disease • Multiple Myeloma • Neutropenia • Thrombocytopenia

Premedication Use and Infusion-Related Reactions in Patients Treated with Subcutaneous Isatuximab: A Pooled Post Hoc Safety Analysis (IMS 2026) - " Pts with RRMM in IRAKLIA (Isa SC: n=263; Isa IV: n=264) and the Phase 1b TCD15484 trial (Isa SC dose-expansion cohort: n=22; Isa IV: n=12) received 1400 mg Isa SC OBI or 10 mg/kg Isa IV plus pomalidomide and dexamethasone (d). In IZALCO, pts with RRMM (n=74) received 1400 mg Isa SC OBI or manual injection plus carfilzomib (K)-d...Premedications included montelukast (C1 only per protocol), steroids (excluding dexamethasone), acetaminophen, H1 antihistamines, and others...In C2, most pts received 2 unique premedications, acetaminophen (Isa SC: 99.0%; Isa IV: 97.5%) and diphenhydramine (or equivalent) (Isa SC: 91.9%; Isa IV: 93.3%); some pts continued montelukast beyond C1, with use declining each cycle... Isa SC injections without premedication were more frequent than Isa IV injections without premedication, and no IRRs occurred with Isa SC injections delivered without premedications. The results support Isa SC as a safe delivery option with low incidence of IRRs."

Clinical • Retrospective data • Hematological Malignancies • Multiple Myeloma

Phase 3 MajesTEC-9: Teclistamab Monotherapy vs Pomalidomide, Bortezomib and Dexamethasone or Carfilzomib and Dexamethasone (Pvd/Kd) in Chinese Patients with Relapsed Refractory Multiple Myeloma (RRMM) (IMS 2026) - P3 | "Introduction: Triplet and quadruplet regimens have greatly improved outcomes in newly diagnosed multiple myeloma, yet a high unmet need remains for more effective, broadly accessible treatments for anti-CD38- and lenalidomide- (Len) exposed/refractory RRMM...In MajesTEC-3, the synergistic Tec-daratumumab combination significantly improved progression-free and overall survival (PFS/OS) as early as first relapse... Consistent with the MajesTEC-9 overall population, Tec monotherapy significantly improved PFS and key secondary endpoints with manageable safety in Chinese RRMM pts with 1–3 prior LOTs. CRS and infections were generally manageable with established protocols. Results from phase 3 MajesTEC-9 study supports the medical adoption of Tec‑based regimens in Chinese pts as early as second‑line therapy regardless of prior anti-CD38/Len exposure."

Clinical • Monotherapy • P3 data • Hematological Malignancies • Infectious Disease • Multiple Myeloma

Phase 2 Study of Selinexor, Carfilzomib, and Dexamethasone in Early Relapsed or Refractory Multiple Myeloma Previously Treated with 1-2 Prior Lines of Therapy (IMS 2026) - "Len-refractory disease was present in 42 pts (87.5%), and 25 (52.1%) were refractory to both len and bortezomib. XKd demonstrated clinically meaningful and durable responses with manageable AEs in early RRMM despite the high prevalence of len-refractory disease. Outcomes appeared more favorable in pts without adverse biologic or functional high-risk features, suggesting that risk stratification may remain important for optimizing treatment outcomes even in early RRMM."

P2 data • Hematological Malignancies • Infectious Disease • Multiple Myeloma • Neutropenia • Respiratory Diseases • Thrombocytopenia